11.87

0.72% 0.0841

Dynavax Technologies Corp (DVAX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Dynavax Technologies Corp stock is traded at $11.87, with a volume of 770.49K. It is up +0.72% in the last 24 hours and up +7.75% over the past month. Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Previous Close:

$11.79

Open:

$11.86

24h Volume:

770.49K

Relative Volume:

0.39

Market Cap:

$1.57B

Revenue:

$236.15M

Net Income/Loss:

$9.22M

P/E Ratio:

30.45

EPS:

0.39

Net Cash Flow:

$52.69M

1W Performance:

+0.55%

1M Performance:

+7.75%

6M Performance:

+1.15%

1Y Performance:

-16.49%

1-Day Range:

$11.76

$12.07

1-Week Range:

$11.61

$12.10

52-Week Range:

$9.74

$15.01

Dynavax Technologies Corp Stock (DVAX) Company Profile

Name

Dynavax Technologies Corp

Sector

Healthcare (1181)

Industry

Drug Manufacturers - Specialty & Generic (88)

Phone

(510) 848-5100

Address

2100 POWELL STREET, EMERYVILLE, CA

Employee

408

Twitter

@DynavaxCorp

Next Earnings Date

2024-11-07

Latest SEC Filings

DVAX's Discussions on Twitter

Dynavax Technologies Corp Stock (DVAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-01-24	Initiated	Goldman	Neutral
Sep-27-22	Initiated	JMP Securities	Mkt Outperform
Jan-06-22	Resumed	Goldman	Buy
Aug-06-21	Initiated	Goldman	Buy
Aug-07-20	Reiterated	H.C. Wainwright	Buy
Aug-03-20	Reiterated	H.C. Wainwright	Buy
Jun-15-20	Initiated	Evercore ISI	Outperform
Oct-18-19	Initiated	H.C. Wainwright	Buy
Jul-11-19	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-27-19	Reiterated	Cantor Fitzgerald	Overweight
May-10-18	Upgrade	JP Morgan	Neutral → Overweight
Mar-08-18	Reiterated	Cantor Fitzgerald	Overweight
Feb-14-18	Downgrade	JP Morgan	Overweight → Neutral
Sep-25-17	Reiterated	RBC Capital Mkts	Outperform
Sep-15-17	Initiated	Cantor Fitzgerald	Overweight
Jul-31-17	Upgrade	JP Morgan	Neutral → Overweight
Jul-31-17	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
May-09-17	Reiterated	RBC Capital Mkts	Sector Perform
Apr-28-16	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Apr-27-16	Downgrade	JP Morgan	Overweight → Neutral
Nov-30-15	Initiated	RBC Capital Mkts	Outperform
Nov-25-13	Upgrade	MLV & Co	Hold → Buy
Feb-25-13	Downgrade	MLV & Co	Buy → Hold
Nov-16-12	Reiterated	MLV & Co	Buy

View All

Dynavax Technologies Corp Stock (DVAX) Latest News

Oct 31, 2024

Dynavax Technologies (DVAX) Set to Announce Quarterly Earnings on Thursday - MarketBeat

Oct 31, 2024

Oct 30, 2024

Dynavax Technologies adopts limited-duration stockholder rights plan - MSN

Oct 30, 2024

Oct 29, 2024

Dynavax Technologies Breaks Above 200-Day Moving AverageBullish for DVAX - Nasdaq

Oct 29, 2024

Dynavax adopts stockholder rights plan amid stake buildu - Investing.com

Oct 29, 2024

Dynavax Adopts Limited-Duration Stockholder Rights Plan - StockTitan

Oct 29, 2024

744,282 Shares in Dynavax Technologies Co. (NASDAQ:DVAX) Purchased by Assenagon Asset Management S.A. - MarketBeat

Oct 29, 2024

Oct 24, 2024

Deep Track Capital, LP Reduces Stake in Dynavax Technologies Cor - GuruFocus.com

Oct 24, 2024

Oct 23, 2024

Dynavax Technologies Corp. (NASDAQ: DVAX) Gains 0.09% In Early Trade; What Lies Ahead? - Stocks Register

Oct 23, 2024

Oct 20, 2024

Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Chicago Capital LLC - MarketBeat

Oct 20, 2024

Oct 16, 2024